Dave Ricks, Eli Lilly
Eli Lilly buys a Roche discard in $1.1B Dermira buyout. Can they go toe-to-toe with the heavyweight challenger Dupixent?
Eli Lilly thinks it has found a better way to tackle the atopic dermatitis market now being dominated by Dupixent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.